Effects of Patient-Driven Lifestyle Modification Using Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: Results From the Randomized Open-label PDF Study

被引:22
|
作者
Choe, Hun Jee [1 ,2 ]
Rhee, Eun-Jung [3 ]
Won, Jong Chul [4 ]
Park, Kyong Soo [1 ,2 ]
Lee, Won-Young [3 ]
Cho, Young Min [1 ,2 ]
机构
[1] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Div Endocrinol & Metab, Dept Internal Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Div Endocrinol & Metab, Dept Internal Med,Sch Med, Seoul, South Korea
[4] Inje Univ, Sanggye Paik Hosp, Div Endocrinol & Metab, Dept Internal Med, Seoul, South Korea
关键词
SENSING TECHNOLOGY; REAL-TIME; NUTRITION; RECOMMENDATIONS; MULTICENTER; MANAGEMENT; ADULTS; CARE;
D O I
10.2337/dc22-0764
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To investigate the effects of patient-driven lifestyle modification using intermittently scanned continuous glucose monitoring (isCGM) in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS We conducted a 12-week, open-label, randomized controlled trial. A total of 126 participants were 1:1 randomized to either the intervention group (structured education + isCGM) or the control group (standard care with blood glucose monitoring). The Self-Evaluation Of Unhealthy foods by Looking at postprandial glucose (SEOUL) algorithm was developed and applied to aid structured education in guiding patients to follow healthy eating behavior depending on the postprandial glycemic response. The primary end point was the change in HbA(1c) level from baseline. RESULTS Implementation of the SEOUL algorithm with isCGM was associated with greater improvement in HbA(1c) than with standard care (risk-adjusted difference -0.50%, 95% CI -0.74 to -0.26, P < 0.001). Participants in the intervention group had a greater reduction in fasting blood glucose and body weight (-16.5 mg/dL, 95% CI -30.0 to -3.0, P = 0.017; -1.5 kg, 95% CI -2.7 to -0.3, P = 0.013, respectively). The score sum for the Korean version of the revised Summary of Diabetes Self-Care Activities Questionnaire increased in both groups but to a greater extent in the intervention group (mean difference 4.8, 95% CI 1.7-8.0, P = 0.003). No severe hyperglycemia or hypoglycemia was reported in either group of patients. CONCLUSIONS Patient-driven lifestyle modification primarily focused on eating behavior using isCGM effectively lowered HbA(1c) levels in patients with T2D.
引用
收藏
页码:2224 / 2230
页数:7
相关论文
共 45 条
  • [41] Effects of Using a Text Message Intervention on Psychological Constructs and the Association Between Changes to Psychological Constructs and Medication Adherence in People With Type 2 Diabetes: Results From a Randomized Controlled Feasibility Study
    Bartlett, Yvonne Kiera
    Farmer, Andrew
    Newhouse, Nikki
    Miles, Lisa
    Kenning, Cassandra
    French, David P.
    JMIR FORMATIVE RESEARCH, 2022, 6 (04)
  • [42] Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study)
    Nomoto, Hiroshi
    Takahashi, Akihiro
    Nakamura, Akinobu
    Kurihara, Hiroyoshi
    Takeuchi, Jun
    Nagai, So
    Taneda, Shinji
    Miya, Aika
    Kameda, Hiraku
    Cho, Kyu Yong
    Miyoshi, Hideaki
    Atsumi, Tatsuya
    BMJ OPEN DIABETES RESEARCH & CARE, 2022, 10 (06)
  • [43] Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study
    Terauchi, Yasuo
    Fujiwara, Hisataka
    Kurihara, Yuji
    Suganami, Hideki
    Tamura, Masahiro
    Senda, Masayuki
    Gunji, Ryoji
    Kaku, Kohei
    JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (06) : 1518 - 1526
  • [44] Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study
    Seino, Yutaka
    Yabe, Daisuke
    Sasaki, Takashi
    Fukatsu, Atsushi
    Imazeki, Hisae
    Ochiai, Hidekazu
    Sakai, Soichi
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (02): : 332 - 340
  • [45] Which is better, high-dose metformin monotherapy or low-dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low-dose metformin monotherapy? A randomized, cross-over, continuous glucose monitoring-based pilot study
    Takahashi, Hiroshi
    Nishimura, Rimei
    Tsujino, Daisuke
    Utsunomiya, Kazunori
    JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (03) : 714 - 722